InvestorsHub Logo
Followers 129
Posts 23648
Boards Moderated 1
Alias Born 09/14/2016

Re: None

Friday, 01/05/2018 3:38:32 PM

Friday, January 05, 2018 3:38:32 PM

Post# of 118421
The NR2F6 program at $RGBP Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity. http://www.stockonhighalert.net/2017/12/rgbp-regen-biopharma-inc-files.html